IN THE SPECIFICATION:

Please enter the following amendment:

Please amend the paragraph encompassing lines 9-15, at page 1, as follows:

This application is a continuation of application serial no. 09/796,581, filed February 27, 2001, currently pending, which is a divisional of application serial no. 09/320,424, filed May 26, 1999, now U.S. Patent 6,284,236, which is a continuation-in-part of application serial no. 09/190,046, filed November 10, 1998, now abandoned~~currently pending~~, which is a continuation-in-part of application serial no. 09/048,641, filed March 26, 1998, now abandoned, which is a continuation-in-part of application serial no. 08/670,354, filed June 25, 1996, now U.S. Patent 5,763,223, which is a continuation-in-part of application serial no. 08/548,368, filed November 1, 1995, now abandoned, which is a continuation-in-part of application serial no. 08/496,632, filed June 29, 1995, now abandoned.

Please amend the paragraph encompassing lines 30-33, at page 14, as follows:

Arap et al. additionally disclose that peptides comprising the tripeptide Asn-Gly-Arg or Gly-Ser-Leu selectively bind to tumors. Among the peptides studied by Arap et al. are the RGD-containing peptide CDCRGDCFC (SEQ ID NO:20), and the NGR-containing peptides CNGRCVSGCAGRC (SEQ ID NO:21), NGRAHA (SEQ ID NO:22), CVLNGRMEC (SEQ ID NO:23), and CNGRC (SEQ ID NO:24).

Please amend the paragraph encompassing lines 7-18, at page 26, as follows:

For expression of TRAIL, a type II protein lacking a native signal sequence, a heterologous signal sequence or leader functional in mammalian host cells may be added. Examples include the signal sequence for interleukin-7 (IL-7) described in United States Patent 4,965,195, the signal sequence for interleukin-2 receptor described in Cosman et al.,

Nature 312:768 (1984); the interleukin-4 receptor signal peptide described in EP 367,566; the type I interleukin-1 receptor signal peptide described in U.S. Patent 4,968,607; and the type II interleukin-1 receptor signal peptide described in EP 460,846. Another option is a leader derived from Ig-kappa ~~(cite)~~, such as a leader comprising the amino acid sequence Met-Gly-Thr-Asp-Thr-Leu-Leu-Leu-Trp-Val-Leu-Leu-Leu-Trp-Val-Pro-Gly-Ser-Thr-Gly (SEQ ID NO:25). Further alternatives are cytomegalovirus-derived leaders and signal peptides derived from a growth hormone, as described in more detail below.

Please amend the paragraph encompassing line 32, at page 26, through line 6, at page 27, as follows:

In another embodiment of the invention, the FLAG® peptide in the fusion protein described immediately above is replaced with a leucine zipper peptide. Thus, one recombinant expression vector provided herein comprises DNA encoding a fusion protein comprising a CMV leader, a leucine zipper peptide, and a soluble TRAIL polypeptide. One example of such a fusion protein is depicted in Figure 4 (SEQ ID NO:13). The protein of Figure 4 comprises (from N- to C-terminus) a CMV leader (residues 1 through 29 of SEQ ID NO:9); an optional tripeptide Thr-Ser-Ser encoded by oligonucleotides employed in vector construction (residues 30 through 32 of SEQ ID NO:9); a leucine zipper (SEQ ID NO:15~~SEQ ID NO:11~~); an optional tripeptide Thr-Arg-Ser encoded by oligonucleotides employed in vector construction; and amino acids 95 to 281 of the human TRAIL protein of SEQ ID NO:2.